Otonomy to Report Third Quarter 2019 Financial Results and Provide Corporate Update
Webcast and Conference Call to be Held at 4:30 p.m. EST on November 5, 2019
Get Alerts OTIC Hot Sheet
Join SI Premium – FREE
SAN DIEGO, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the third quarter 2019 as well as provide a corporate update at 4:30 p.m. EST on November 5, 2019.
The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 6045449. A live webcast of the call will be available online in the investor relations section of Otonomy’s website at www.otonomy.com and will be archived there for 30 days.
About OtonomyOtonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière’s disease, hearing loss, and tinnitus. For additional information please visit www.otonomy.com.
Contacts:
Media InquiriesSpectrum ScienceLeticia DiazVice President202.587.2517[email protected] Investor InquiriesWestwicke ICRRobert H. UhlManaging Director858.356.5932[email protected]
Source: Otonomy, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan is worried about further S&P 500 sell-off potential
- Tesla, GM earnings, US futures, EV sales - what's moving markets
- Recording of LHV Group's 23 April investor webinar
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!